Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort.
Margret Jona EinarsdottirBrian K KiruiHuiqi LiDaniel S OlssonGudmundur JohannssonFredrik NybergOskar RagnarssonPublished in: BMJ open (2024)
Patients on oral GC treatment prior to COVID-19 have increased mortality, particularly from pulmonary embolism, sepsis and COVID-19.
Keyphrases
- pulmonary embolism
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- intensive care unit
- acute kidney injury
- inferior vena cava
- cardiovascular disease
- type diabetes
- combination therapy
- coronary artery disease
- mass spectrometry
- respiratory syndrome coronavirus
- drug induced